27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
In 2012, the national prevalence of antipsychotic drug use was 20.7% for elderly patients with dementia, with a national incidence of 3.9%. 4 key findings →
Design: cross-sectional Participants: 34,536 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The prevalence of cognitive impairment, MCI, and dementia among participants aged 60 years and older were 21.48% (95% CI, 19.90-23.10), 15.70% (95% CI, 14.30-17.10), and 5.77 (95% CI, 4.90-6.70), respectively. 5 key findings →
Design: cross-sectional Participants: 3,233 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.041). Socioeconomic status and residential area are associated with long-term survival in patients with EOD. 2 key findings →
Design: cohort study Participants: 3,825 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The number of people living with dementia worldwide is growing. 3 key findings →
Design: meta-analysis Participants: 1,636 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
ADI groups differed by sex, ethnoracial background, and MMSE scores. 5 key findings →
Design: cohort study Participants: 755 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
High correlations between plasma and serum were observed for most assays (ρ > 0.8), though plasma often yielded higher concentrations. 5 key findings →
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study included 197 patients in whom lecanemab infusions had been started (lecanemab group), as well as 173 patients in whom lecanemab had been ordered but not yet started, who were combined with 1139 research participants with cognitive impairment from the Knight ADRC cohort to form the untreated control group with cognitive impairment (n=1312). 5 key findings →
Design: cohort study Participants: 1,312 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
RBC DHA was associated with a positive (improved) global cognition (PACC) rate of change (estimate: 0.011; 95% CI: 0.001, 0.021; P = 0.024). 5 key findings →
Design: longitudinal study Participants: 323 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 203 enrolled patients, 186 (mean [SD] age, 68.7 [5.2] years; 119 males [64.0%]) were randomized (137 to the CN-105 group, 49 to the placebo group) and underwent surgery. 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Thirty medical specialists (geriatricians, n = 23; psychiatrists, n = 4; neurologists, n = 3) from 30 different clinics participated (public, 76.7%; private, 23.3%), including from metropolitan (73.3%), regional (20.0%) and rural (6.7%) areas. 5 key findings →
Design: cross-sectional Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 282 participants were followed for an average of 2.9 years (standard deviation [SD] 1.3 years). 5 key findings →
Participants: 282 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This special issue of Alzheimer's & Dementia celebrates the accomplishments of the Alzheimer's Disease Neuroimaging Initiative (ADNI) project as it approaches its 20th anniversary in 2024, supported by funding from the National Institute on Aging. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cerebral amyloid angiopathy (CAA) is a cerebrovascular disorder characterized by the deposition of amyloid-β (Aβ) in the walls of leptomeningeal and cortical blood vessels that increases risk of intracerebral hemorrhages and progressive cognitive decline. 2 key findings →
Participants: 251 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Glaucoma is a major ocular neurodegenerative disease and a leading cause of irreversible blindness worldwide, with prevalence projected to exceed 110 million by 2040. 3 key findings →
Design: cross-sectional Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among 5,145 participants included in the analyses, 747 (14.5 %) reported hearing loss, including 207 Black adults and 199 White adults. 5 key findings →
Design: cohort study Participants: 5,145 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Diabetic complications represent a formidable clinical challenge characterized by hyperglycemia-induced multiorgan dysfunction and dysregulated intercellular signaling networks. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Recent studies support the influence of paternal lifestyle and diet before conception on the health of the offspring via epigenetic inheritance through sperm DNA methylation, histone modification, and small non-coding RNA (sncRNA) expression and regulation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cancer is a long-term illness that involves an imbalance in cellular and immune functions. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In the complex realm of cognitive disorders, Alzheimer's disease (AD) and vascular dementia (VaD) are the two most prevalent dementia types, presenting entangled symptoms yet requiring distinct treatment approaches. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These lessons emphasize the importance of ensuring tests are feasible across both high-income countries and LMICs, maintaining consistency within studies and over time, and designing comprehensive cognitive batteries for improved measurement precision of general and domain-specific phenotypes. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
It is generally assumed that dementia affects the quality of optical coherence tomography (OCT) scans. 3 key findings →
Design: cross-sectional Participants: 112 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 822 individuals enrolled in the HEAD study, 681 participants spanning cognitively unimpaired to dementia were included. 5 key findings →
Design: cross-sectional Participants: 681 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These analyses suggest that CenTauR harmonization increases the comparability of tau‐PET data acquired with different tracers. 2 key findings →
Design: longitudinal study Participants: 1,089 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cerebellar volumetric changes are intricately linked to aging, with distinct patterns across its transverse zones, the functional subdivisions characterized by unique cytoarchitectural and connectivity profiles. 5 key findings →
Participants: 45,000 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Nearly half (48%) of older adults experienced an inpatient admission, and nearly all (92%) experienced a potentially burdensome intervention. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →